Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Onconetix, Inc.BWV · Entity 8471 | Chief Business Officer | May 09, 2023 | May 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Onconetix, Inc.
Report date May 09, 2023 · Filed May 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,752 |
Reported balance
After 2023-05-09 transaction · row 1
1 source rowRow 1 · 2023-05-09 · Grant · Acquired 150,000 · Balance 174,752 F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2023 Filed May 11, 2023 21:18 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-038666 · ownership.xml · nonDerivative · entry 1 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,752 F1 · price: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 21:59 UTC | Onconetix, Inc. BWV · Entity 8471 | Tax withholdingStock Option · Derivative | 4,834 | $0.01 Strike: $0.01 | $48.34 |
DisclosureSEC source: 0001213900-22-050239 · ownership.xml · derivative · entry 5 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,276 Underlying: Common Stock · 4,834 shares Expires 2030-04-02 Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 21:59 UTC | Onconetix, Inc. BWV · Entity 8471 | SaleCommon Stock | 4,834 | $3.97 | $19,190.98 |
DisclosureSEC source: 0001213900-22-050239 · ownership.xml · nonDerivative · entry 3 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,752 F1 · price: The Common Stock reported herein were sold by the reporting person at a high price of $4.00, a low price of $3.96 and an average price of $3.97 per share of Common Stock. Upon request, the reporting person will provide details of each sale. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 21:59 UTC | Onconetix, Inc. BWV · Entity 8471 | Tax withholdingCommon Stock | 4,834 | $0.01 | $48.34 |
DisclosureSEC source: 0001213900-22-050239 · ownership.xml · nonDerivative · entry 2 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,586 Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:59 UTC | Onconetix, Inc. BWV · Entity 8471 | Tax withholdingStock Option · Derivative | 24,810 | $0.01 Strike: $0.01 | $248.10 |
DisclosureSEC source: 0001213900-22-050239 · ownership.xml · derivative · entry 4 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,110 Underlying: Common Stock · 24,810 shares Expires 2030-04-02 Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:59 UTC | Onconetix, Inc. BWV · Entity 8471 | Tax withholdingCommon Stock | 24,752 | $0.01 | $247.52 |
DisclosureSEC source: 0001213900-22-050239 · ownership.xml · nonDerivative · entry 1 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,752 Read SEC document |
| May 04, 2022 Filed May 27, 2022 10:39 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001213900-22-029993 · ownership.xml · derivative · entry 1 Henderson Erin · CIK 0001895467 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,920 Underlying: Common Stock, par value $0.00001 per share · 200,000 shares Expires 2032-05-04 F1 · derivative.exercise_date: Stock options (the "Options") were granted to Ms. Henderson on May 4, 2022. The Options vest and become exercisable as follows (i) 127,800 Options vested immediately upon grant; (ii) 1,306 Options vest at the end of each calendar month from the date of issuance through December 31, 2023 and (iii) 1,920 Options vest at the end of each calendar month thereafter through December 31, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.